5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | BUY | BUY |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 50.75▲ | 50.75▲ | 50.75▲ | 50.78▲ | 50.71▲ |
MA10 | 50.73▲ | 50.73▲ | 50.73▲ | 50.75▲ | 50.50▲ |
MA20 | 50.69▲ | 50.67▲ | 50.67▲ | 50.70▲ | N/A |
MA50 | 50.62▲ | 50.47▲ | 50.40▲ | 50.46▲ | N/A |
MA100 | N/A | N/A | N/A | N/A | N/A |
MA200 | N/A | N/A | N/A | N/A | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.003▲ | -0.002▼ | -0.007▼ | -0.005▼ | N/A |
RSI | 79.992▲ | 78.308▲ | 78.057▲ | 68.372▲ | N/A |
STOCH | 78.222 | 77.024 | 77.024 | 61.378 | N/A |
WILL %R | 0.000▲ | 0.000▲ | 0.000▲ | -12.000▲ | N/A |
CCI | 219.438▲ | 161.828▲ | 161.828▲ | 145.404▲ | N/A |
Thursday, April 18, 2024 01:57 PM
Enliven Therapeutics (NASDAQ:ELVN) on Thursday filed a prospectus related to the proposed resale of about 6.43M shares of its common stock by selling stockholders. This prospectus is not an offer to ...
|
Monday, April 15, 2024 09:14 AM
To wrap up, the performance of Enliven Therapeutics Inc (ELVN) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that ...
|
Sunday, April 14, 2024 04:32 PM
Enliven Therapeutics Inc., a clinical-stage precision oncology company, has appointed physician Lori Kunkel to its board of directors.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
26/04/24 | 50.80 | 50.8476 | 50.7963 | 50.8476 | 26,954 |
25/04/24 | 50.7203 | 50.76 | 50.71 | 50.72 | 1,375 |
24/04/24 | 50.80 | 50.81 | 50.78 | 50.78 | 9,013 |
23/04/24 | 50.74 | 50.76 | 50.735 | 50.76 | 10,588 |
22/04/24 | 50.84 | 50.895 | 50.7885 | 50.7886 | 12,934 |
19/04/24 | 50.725 | 50.725 | 50.72 | 50.725 | 1,098 |
18/04/24 | 50.71 | 50.76 | 50.71 | 50.76 | 2,824 |
17/04/24 | 50.72 | 50.72 | 50.69 | 50.69 | 35,628 |
16/04/24 | 50.69 | 50.71 | 50.655 | 50.71 | 15,050 |
15/04/24 | 50.65 | 50.7417 | 50.65 | 50.71 | 12,840 |
|
|
||||
|
|
||||
|
|